Psychedelics have left the counterculture—and entered the boardroom. In this episode, we explore why a growing number of companies are embracing substances like ketamine, psilocybin, and MDMA as tools for employee well-being and executive performance. From biotech investors betting on psychedelic medicine to firms like Dr. Bronner’s offering ketamine therapy as a workplace benefit, the corporate world is reframing these drugs as pathways to better mental health, reduced anxiety, and even enhanced creativity. Some leaders are going further, hosting psychedelic-inspired retreats meant to deepen empathy and strengthen team bonds. But with these breakthroughs come big risks: misuse, blurred boundaries, and the possibility that an employee’s “expanded perspective” may prompt them to question their job—or the entire company. Are psychedelics the next f ...